amivantamab

Showing 1 posts of 1 posts found.

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026
SMC, amivantamab, lazertinib, lung cancer

The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for use within NHS Scotland as …

The Gateway to Local Adoption Series

Latest content